A randomized controlled trial on lactoferrin versus ferrous sulphate for the treatment of mild to moderate iron deficiency anaemia in pregnancy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20200336Keywords:
Anaemia, Ferrous sulphate, Haemoglobin, Iron deficiency anaemia, Lactoferrin, Pregnancy, Serum Iron, Total iron binding capacityAbstract
Background: One of the important factors associated with maternal and foetal complications during pregnancy is Anaemia. Various oral preparations of iron are available, and each has different bioavailability, efficacy and adverse effects. Lactoferrin is a naturally existing iron-binding multifunctional glycoprotein, and a member of a transferrin family, thus belonging to those proteins capable of binding and transferring iron. Lactoferrin has considerably less gastrointestinal side effects than ferrous sulfate and is very useful as well as promising alternative to ferrous sulphate.
Methods: Prospective randomized controlled study. Total 100 females with 24 to 36 weeks of pregnancy with haemoglobin between 8 to 10 grams were included out of which 50 patients were given ferrous sulphate 200 mg BD and 50 patients were given lactoferrin 250 mg BD daily for 8 weeks. Various haematological parameters and the adverse effects of both the drugs were studied at registration, 4 weeks and 8 weeks and compared.
Results: Thus, after this study authors can say that the rise in haemoglobin with lactoferrin was 1.58 g/dl while with ferrous sulphate it was 1.67 g/dl at 8 weeks. Adverse effects were much lesser in Group A taking lactoferrin compared to Group B.
Conclusions: Thus, lactoferrin has the advantage over ferrous sulphate in having less side effects and increasing the compliance and thus the efficacy of the drug compared to ferrous sulphate.
References
Rezk M, Dawood R, Abo-Elnasr M, Halaby AA, Marawan H. Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anaemia during pregnancy: a randomized clinical trial. J Matern Fetal Neonatal Med. 2015:1-4.
Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Carlo CD. Department of Gynecology and Obstetrics, University of Naples” Federico II”, Naples Italy Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anaemia: a prospective controlled randomized study. Acta Obstetricia et Gynecologica. 2009:88:1031-5.
Rezk M, Kandil M, Dawood R, Shaheen AE, Allam A. Oral lactoferrin versus ferrous sulphate and ferrous fumarate for the treatment of iron deficiency anaemia during pregnancy. J Adv Nutrit Human Metabol. 2015;2:e740.
Paesano R, Pacifici E, Benedetti S, Berlutti F, Frioni A, Polimeni A, et al. Safety and efficacy of lactoferrin versus ferrous sulphate in curing iron deficiency and iron deficiency anaemia in hereditary thrombophilia pregnant women: an interventional study. Biometals. 2014;27(5):999-1006.
Hemeda HM, Mohamed AAK, Islam BA, Hasan A, Ewies A. Effectiveness of bovine lactoferrin versus ferrous fumarate in the management of iron deficiency anemia in pregnancy: randomized clinical trial. Int J Repro Med Gynecol. 2018;4(1):006-011.
Paesano R, Torcia F, Berlutti F, Pacifici E, Ebano V, Moscarini M, et al. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. 2006;84:377-80.
Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72:257-64.
De Domenico I, Ward MD, Kaplan I. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol. 2008;9:72-81.
Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism. 2005;1(3):191-200.
Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Hematol J. 2006;91:727-32.
